<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710524</url>
  </required_header>
  <id_info>
    <org_study_id>FM101-CTP2-001</org_study_id>
    <nct_id>NCT04710524</nct_id>
  </id_info>
  <brief_title>FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis</brief_title>
  <official_title>A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Future Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Future Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and&#xD;
      Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease or Nonalcoholic&#xD;
      Steatohepatitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">July 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of 13 weeks of treatment with FM101 in patients with NAFLD or NASH</measure>
    <time_frame>Day 1 through Day 106</time_frame>
    <description>The number of TEAEs (frequency of occurrence, number of subjects experiencing the event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the treatment effect of FM101 on serum ALT concentrations during 13 weeks of treatment</measure>
    <time_frame>Day 1 through Day 91</time_frame>
    <description>Changes in serum ALT level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of 13 weeks of treatment with FM101 on the change in liver stiffness (kPa) measured by magnetic resonance imaging-magnetic resonance elastography (MRI MRE) in patients with NAFLD or NASH</measure>
    <time_frame>Day 1 through Day 91</time_frame>
    <description>Change in liver stiffness on MRE</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>orally administer placebo BID for 13 weeks except on Day 91 subject receive a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 150 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally administer FM101 150mg BID for 13 weeks except on Day 91 subject receive a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FM101 300 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally administer FM101 300mg BID for 13 weeks except on Day 91 subject receive a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID for 13 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FM101 150 mg BID</intervention_name>
    <description>FM101 (150 mg) BID for 13 weeks</description>
    <arm_group_label>FM101 150 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FM101 300 mg BID</intervention_name>
    <description>FM101 (300 mg) BID for 13 weeks</description>
    <arm_group_label>FM101 300 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals must meet all of the following criteria to be included in the study:&#xD;
&#xD;
          1. Be able and willing to provide written informed consent to take part in the study, and&#xD;
             to comply with all the study's requirements.&#xD;
&#xD;
          2. Be a man or woman ≥18 years of age at screening.&#xD;
&#xD;
          3. Have c. Histologic confirmation of NASH no more than 12 months before the screening&#xD;
             visit date, demonstrating the existence of steatosis ≥5%, hepatocyte ballooning and&#xD;
             chronic inflammation (at least 1 point for each component), and stage 1 through stage&#xD;
             3 liver fibrosis according to the NASH Clinical Research Network (CRN); OR d. NAFLD&#xD;
             based upon demonstration of at least 3 of the following 5 components of the metabolic&#xD;
             syndrome below, at screening:&#xD;
&#xD;
               -  Fasting plasma glucose ≥100 mg/dL , or undergoing drug treatment for elevated&#xD;
                  plasma glucose concentrations&#xD;
&#xD;
               -  High-density lipoprotein-cholesterol (HDL-c) concentration &lt;40 mg/dL in male&#xD;
                  patients, or &lt;50 mg/dL in female patients, or undergoing drug treatment for&#xD;
                  reduced serum HDL-c concentrations&#xD;
&#xD;
               -  Serum triglyceride (TG) concentration ≥150 mg/dL, or undergoing drug treatment&#xD;
                  for elevated serum TG concentrations&#xD;
&#xD;
               -  Waist circumference &gt;102 cm in male patients or &gt;88 cm in female patients&#xD;
&#xD;
               -  Systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg, or&#xD;
                  undergoing drug treatment for hypertension, or antihypertensive drug treatment in&#xD;
                  a patient with a history of systemic hypertension&#xD;
&#xD;
          4. Serum ALT concentration &gt;1 × upper limit of normal (ULN) at screening&#xD;
&#xD;
          5. Undergo MRI-PDFF that demonstrates ≥8% liver steatosis during the screening period.&#xD;
&#xD;
          6. Undergo MRE with a score ≥2.9 kPa during the screening period.&#xD;
&#xD;
          7. Women of childbearing potential (WoCBP) must have a negative serum beta human&#xD;
             chorionic gonadotropin (HCG) test result at screening.&#xD;
&#xD;
             Female patients must agree to use highly effective birth control throughout the study&#xD;
             and up to 30 days after the last dose of study drug has been taken. Highly effective&#xD;
             contraception measures include the following, but not limited to:&#xD;
&#xD;
               -  Combined estrogen- and progestogen-containing hormonal contraception (oral,&#xD;
                  intravaginal and transdermal);&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (oral, injectable, and implantable);&#xD;
&#xD;
               -  Intrauterine device, intrauterine hormone-releasing system, bilateral tubal,&#xD;
                  occlusion ('tubal occlusion' includes 'tubal ligation');&#xD;
&#xD;
               -  Vasectomized partner (only in the event that the vasectomized partner is the sole&#xD;
                  sexual partner of the WoCBP);&#xD;
&#xD;
               -  Sexual abstinence (defined as refraining from heterosexual intercourse) only in&#xD;
                  the event that this is the preferred lifestyle of the patient.&#xD;
&#xD;
             Childbearing potential is defined as being fertile following menarche and until&#xD;
             becoming postmenopausal unless permanently sterile (hysterectomy, bilateral&#xD;
             salpingectomy, or bilateral oophorectomy).&#xD;
&#xD;
             A postmenopausal state is defined as no menses for ≥12 consecutive months without an&#xD;
             alternative medical cause.&#xD;
&#xD;
             Men with partners who are WOCBP must either be surgically sterile or agree to use a&#xD;
             barrier contraceptive for the duration of the study and up to 30 days after the last&#xD;
             dose of study drug.&#xD;
&#xD;
          8. Be willing to maintain a stable diet, including alcohol intake this applies, and&#xD;
             physical activity throughout the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals meeting any of the following criteria at screening or baseline are ineligible&#xD;
        to participate in this study:&#xD;
&#xD;
          1. Any patient who refuses to provide written informed consent to take part in the study,&#xD;
             and/or appears unwilling to comply with study-specific requirements.&#xD;
&#xD;
          2. Female persons who are pregnant, or are breastfeeding at screening, or who plan to&#xD;
             become pregnant during the study.&#xD;
&#xD;
          3. Body mass index (BMI) &lt;25 kg/m2.&#xD;
&#xD;
          4. Fibrosis-4 index (FIB-4) &gt;2.6 at screening.&#xD;
&#xD;
          5. Any of the following laboratory test abnormalities at screening:&#xD;
&#xD;
               1. Serum ALT and/or AST concentration &gt;5 × upper limit of normal (ULN)&#xD;
&#xD;
               2. Total serum bilirubin (BR) concentration &gt;ULN; if an established diagnosis of&#xD;
                  Gilbert's syndrome exists and the direct serum BR result at screening is less&#xD;
                  than or equal to ULN the patient may participate in the study&#xD;
&#xD;
               3. Serum albumin concentration ≤3.5 g/dL&#xD;
&#xD;
               4. International normalized ratio (INR) ≥1.3&#xD;
&#xD;
               5. Platelet count less than the lower limit of normal range (LLN)&#xD;
&#xD;
               6. Creatinine clearance rate &lt;60 mL/minute as calculated by the modification of diet&#xD;
                  in renal disease (MDRD) estimated glomerular filtration rate (eGFR) equation&#xD;
&#xD;
               7. Positive COVID-19 polymerase chain reaction (PCR) test result at screening NOTE:&#xD;
                  Repeat testing of a given parameter or parameters that returned ineligible&#xD;
                  results, may be performed during the same screening period in consultation with&#xD;
                  the sponsor's Medical Monitor. An interval of at least 7 days should exist&#xD;
                  between receipt of the ineligible test result and re-testing.&#xD;
&#xD;
          6. Chronic liver disease other than confirmed or suspected NASH, including but not&#xD;
             limited to the following diagnoses / entities:&#xD;
&#xD;
               1. Chronic hepatitis B virus infection (defined by the presence of hepatitis B&#xD;
                  surface antigen at screening) and / or chronic hepatitis C virus (HCV) infection&#xD;
                  (defined by the presence of detectable HCV ribonucleic acid (RNA) antibody&#xD;
                  [anti-HCV] at screening). Patients whose anti-HCV antibody test at screening is&#xD;
                  positive, but who test negative for HCV RNA at screening will be permitted to&#xD;
                  participate in the study as long as there has been evidence of viral negativity&#xD;
                  for at least 24 months prior to screening)&#xD;
&#xD;
               2. Autoimmune hepatitis (AIH), or confirmed overlap syndrome of AIH and either&#xD;
                  primary biliary cholangitis or primary sclerosing cholangitis.&#xD;
&#xD;
               3. Primary biliary cholangitis, primary sclerosing cholangitis, secondary sclerosing&#xD;
                  cholangitis whatever the basis for this, e.g. chronic pancreatitis resulting in&#xD;
                  bile duct stricture formation, recurrent extrahepatic bile duct calculus&#xD;
                  formation, arterial insult resulting in bile duct stricture formation&#xD;
&#xD;
               4. Wilson's disease, homozygous alpha-1-anti-trypsin deficiency, hemochromatosis,&#xD;
                  drug-induced liver disease&#xD;
&#xD;
               5. Alcoholic liver disease&#xD;
&#xD;
               6. Suspected or confirmed hepatocellular carcinoma&#xD;
&#xD;
          7. Medical, histologic, and/or imaging history of hepatic cirrhosis.&#xD;
&#xD;
          8. Clinical, endoscopic, imaging and/or laboratory manifestations of portal hypertension,&#xD;
             such as spider nevi, splenomegaly, clinically evident ascites formation, non-bleeding&#xD;
             gastro-oesophageal varices.&#xD;
&#xD;
          9. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         10. Chronic use (≥12 months) of any drug known to be associated with development of NAFLD&#xD;
             during the five years before the anticipated Day 1 visit date, e.g. amiodarone,&#xD;
             methotrexate, systemic glucocorticoids (unless employed at physiologic replacement&#xD;
             doses for management of confirmed adrenal insufficiency), tetracyclines, tamoxifen,&#xD;
             estrogens at doses greater than those used for hormone replacement therapy, anabolic&#xD;
             steroids (other than testosterone replacement preparations being taken at a&#xD;
             physiologic replacement dose for management of confirmed male hypogonadism), sodium&#xD;
             valproate, and other hepatotoxins, e.g. minocycline.&#xD;
&#xD;
         11. Use of the following medications:&#xD;
&#xD;
               1. GLP-1 agonists, unless on a stable dose for at least 3 months prior to screening&#xD;
&#xD;
               2. Thiazolidinediones, obeticholic acid or vitamin E at a daily dose &gt;400 IU daily&#xD;
                  within the 6 months before screening&#xD;
&#xD;
               3. Statin therapy and other lipid-modifying therapies must have been used at a&#xD;
                  stable dose for ≥3 months prior to screening&#xD;
&#xD;
               4. Oral antidiabetic medication(s) (other than those specifically excluded) must&#xD;
                  have been used / taken at a stable daily dose for ≥3 months prior to screening&#xD;
&#xD;
         12. History of significant alcohol consumption, defined as an average of &gt;20 g/day in&#xD;
             female patients and &gt;30 g/day in male patients, for a period of &gt;3 consecutive months&#xD;
             within 1 year prior to screening, hazardous alcohol use (Alcohol Use Disorders&#xD;
             Identification Test score ≥8), or an inability to reliably quantify alcohol&#xD;
             consumption based upon judgment of the investigator.&#xD;
&#xD;
         13. Active substance abuse within the 1 year before the screening visit date, upon the&#xD;
             judgement of the investigator.&#xD;
&#xD;
         14. Weight change ≥7% within the 6 months prior to screening or ≥5% within the 3 months&#xD;
             prior to screening.&#xD;
&#xD;
         15. Prior or planned (during the study period) weight reduction surgery, e.g. sleeve&#xD;
             gastrectomy, Roux-en-Y gastrojejunostomy.&#xD;
&#xD;
         16. Type 1 diabetes mellitus by medical history.&#xD;
&#xD;
         17. Poorly controlled type 2 diabetes mellitus (this is defined as hemoglobin A1c (HbA1c)&#xD;
             &gt;9.5% at screening, or a patient whose oral anti-diabetic medication dosing requires&#xD;
             adjustment &gt;10% less than 2 months before the screening visit date.&#xD;
&#xD;
         18. Uncontrolled systemic hypertension (either treated or untreated) defined as systolic&#xD;
             blood pressure &gt;160 mmHg or a diastolic blood pressure &gt;100 mmHg at screening. A&#xD;
             retest of blood pressure, (after establishing good blood pressure control within a&#xD;
             reasonable period of time and up to the Baseline visit) is permissible at the&#xD;
             discretion of the Investigator.&#xD;
&#xD;
         19. Patients who demonstrate recent evidence (within 6 months of the anticipated date of&#xD;
             the Day 1 visit) of clinically evident and significant atheromatous cardiovascular&#xD;
             disease, e.g. unstable angina, acute coronary syndrome, myocardial infarction,&#xD;
             cerebrovascular accident [stroke], cerebrovascular ischemia, transient ischemic&#xD;
             attack, and / or peripheral vascular disease requiring intervention.&#xD;
&#xD;
         20. Has taken part in a clinical trial and been administered an active investigational&#xD;
             product being evaluated for the treatment of NASH, weight reduction and / or type 2&#xD;
             diabetes mellitus, during the 6 months prior to the anticipated Day 1 visit date.&#xD;
&#xD;
         21. Has participated in an investigational new drug trial during the 30 days prior to&#xD;
             screening visit date, or within 5 half-lives of an investigational agent, whichever is&#xD;
             longer.&#xD;
&#xD;
         22. Has a confirmed diagnosis of malignancy within 5 years prior to screening, except for&#xD;
             basal- or squamous-cell carcinoma of the skin that has been treated successfully, or&#xD;
             cervical carcinoma in situ that has been treated successfully. Patients with a history&#xD;
             of other malignancies that have been treated with curative intent and who have no&#xD;
             demonstrable disease recurrence within 5 years prior to screening may also be eligible&#xD;
             if approved following discussion with the Sponsor's Medical Monitor. Patients under&#xD;
             evaluation for malignant disease currently are not eligible for study participation.&#xD;
&#xD;
         23. Patients who are unable to undergo MRI studies, whatever the reason for this, e.g.&#xD;
             claustrophobia, the presence of a device or implant that would make imaging dangerous&#xD;
             for the patient.&#xD;
&#xD;
         24. Any other condition which, in the opinion of the Investigator, would impede compliance&#xD;
             with, hinder completion of the study, compromise the well-being of the patient, and /&#xD;
             or interfere with the study's endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WanSeok Jeong, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Future Medicine Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyounghee Kim, MS</last_name>
    <phone>+8222898540</phone>
    <email>kkh@futuremedicine.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saehan Kang, MS</last_name>
    <phone>+82232873805</phone>
    <email>saehan@futuremedicine.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Semmelweis Egyetem I. sz. Sebészeti és Intervenciós Gasztroenterológiai Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Klára Werling, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Health Kft.,</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tamás Nyéky, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne sp z o.o.</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Rozpondek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ID Clinic Arkadiusz Pisula</name>
      <address>
        <city>Mysłowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Janczewska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Kierkus</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne K2J2</name>
      <address>
        <city>Wołomin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Kuc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych Piotr Napora lekarze</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Simon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Pericas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Crespo Garcia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio (HUVR)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Romero-Gomez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moises Diago Madrid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clnico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Desamparados Escudero-Garcia</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>FM101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

